Adjunctive Tirofiban Gains Ground in Stroke
Recent trials have shown that adjunctive tirofiban can benefit select acute ischemic stroke patients without significant safety concerns. The INSTANT trial indicated improved outcomes for patients with inadequate responses to thrombolysis, while the ATTRACTION trial highlighted its effectiveness post-thrombectomy. Overall, these findings suggest that tirofiban may enhance recovery in high-risk stroke patients.
- ▪Tirofiban, an antiplatelet agent, was evaluated in three trials for its efficacy in acute ischemic stroke patients.
- ▪The INSTANT trial demonstrated that intravenous tirofiban improved outcomes in patients who did not respond adequately to thrombolysis.
- ▪The ATTRACTION trial found that intra-arterial tirofiban after thrombectomy significantly improved functional outcomes.
Opening excerpt (first ~120 words) tap to expand
Adjunctive intravenous or intra-arterial administration of the antiplatelet agent, tirofiban, showed benefit with no apparent safety issues in select acute ischemic stroke patients across three newly reported trials.Tirofiban, a potent glycoprotein IIb/IIIa inhibitor class commonly used in acute coronary syndromes was evaluated as an adjunctive antiplatelet strategy in three different stroke settings.The INSTANT trial showed that intravenous tirofiban improved outcomes in patients with acute ischemic stroke who had an inadequate early clinical response to thrombolysis, and no large or medium vessel occlusion or cardioembolic stroke.“These findings indicate that early tirofiban administration has the potential to significantly improve functional recovery in a select group of acute ischemic…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
